Visit our foundation to give a gift.
View Locations Near Me
Main Campus – Hartford
Connecticut Children’s – Waterbury
Urgent Care – Farmington
Specialty Care Center – Danbury
Connecticut Children’s Surgery Center at Farmington
Specialty Care Center – Westport
Search All Locations
Find a doctor
Find A Doctor
Amenities and Services
Who’s Who on Care Team
Getting Ready for Surgery
What to Expect—Picture Stories
Pay a Bill
Understanding the Different Fees
Pricing Transparency and Estimates
Raytheon Technologies Family Resource Center
Family Advisory Council
Legal Advocacy: Benefits, Education, Housing
Electronic Health Records
Share Your Story
Pay a Bill
Login to MyChart
Clinical Support Services Referrals
About the Network
Join the Network
Graduate Medical Education
Continuing Medical Education
MOC/Practice Quality Improvement
Educating Practices in the Community (EPIC)
Learning & Performance
Meet our Physician Relations Team
Request Medical Records
Join our Referring Provider Advisory Board
View our Physician Callback Standards
Read & Subscribe to Medical News
Register for Email Updates
Update Your Practice Information
Refer a Patient
Monica Buchanan, Senior Director, Strategic Communications
Hartford, CT (Jan 12, 2023)- The National Institutes of Health (NIH) has awarded Juan C. Salazar, MD, Physician-in-Chief at Connecticut Children’s and expert in infectious diseases and immunology, one of eight research grants to refine new technologies for early diagnosis of severe illnesses resulting from SARS-CoV-2 (COVID-19) infection in children. The new awards follow grants issued in 2020 to foster methods for diagnosing children at high risk for Multisystem Inflammatory Syndrome in Children (MIS-C), a rare, severe, and sometimes fatal after-effect of SARS-CoV-2 infection or exposure in children.
This grant award will allow Dr. Salazar and his team of researcher colleagues to continue their efforts to develop a tool that can easily diagnose MIS-C, which presents similar symptoms to COVID-19 and to Kawasaki disease, another rare condition affecting children. Faster identification of those most at risk will allow for earlier interventions to prevent severe health effects.
“We’re trying to use bedside point-of-care technology to help differentiate COVID vs. Kawasaki vs. MIS-C,” Salazar said, “which is a big problem right now because we don’t have a good way of doing that readily at this point.”
The study is a collaborative effort involving researchers from the University of Connecticut Storrs, University of Connecticut Health Center, the Jackson Laboratory for Genomic Medicine, New York Department of Health, New York University, and the Food and Drug Administration. Over the past two years, 630 children with MIS-C, COVID-19, Kawasaki disease, respiratory viral disease, and no disease (healthy controls) have been enrolled from sites in Connecticut and Cali, Colombia, and their blood and saliva have been studied to identify proteins and bacteria that are unique to MIS-C. The point-of-care test is using cutting-edge chip technology developed by Ciencia, Inc. (East Harford, CT) that can test for multiple proteins simultaneously. Preliminary results are promising, with the identification of 19 proteins that distinguish between MIS-C and other diagnoses, and eight proteins that distinguish between MIS-C and Kawasaki disease.
Salazar says the technology could have broader implications. “If it goes well, this kind of diagnostic capability could be used for many other conditions,” Salazar said. “This chip could be quite innovative, and it’s being built right here in East Hartford.”
The awards come from NIH’s Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) initiative.
“These highly innovative technologies and tools have the potential to greatly improve the care of children with SARS-CoV-2 infection and other fever-causing illnesses,” said Bill Kapogiannis, M.D., of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which oversees the grants.
Although some children develop mild or no symptoms from COVID-19, others will develop more severe effects, including MIS-C, which results in inflammation of one or more organs, including the heart, lungs, kidneys, brain, skin, eyes and gastrointestinal tract. MIS-C first emerged in Connecticut in the spring of 2020, appearing in children weeks after they experienced asymptomatic COVID-19. The CDC reports an MIS-C death rate of 0.8% and 0.7% for pediatric COVID-19. Dr. Salazar and his team at the Connecticut Children’s Research Institute are also part of the RECOVER initiative, a national study created by the NIH to study the long term effects of COVID-19 in children, including complications associated to MIS-C.
About Connecticut Children’s
Connecticut Children’s is the only hospital in Connecticut dedicated exclusively to the care of children and ranked one of the best children’s hospitals in the nation by U.S. News & World Report and a Magnet® designated hospital. Connecticut Children’s provides more than 30 pediatric specialties along with community-based programs to uniquely care for the physical, social, and emotional needs of children. Our team of pediatric experts and care coordinators bring access to breakthrough research, advanced treatments for both rare and common diseases, and innovative health and safety programs to every child. Connecticut Children’s is a not-for-profit organization with a mission to improve access to healthcare for all children through convenient locations, care alliances and partnerships.